Acquisition of APIRx

onal use only For per The acquisition of APIRX delivers a strong portfolio of patented drug candidates, with 22 development programs covering a total addressable market of US$400B per annum. Together, Incannex and APIRX will form the world's largest portfolio of patented medicinal cannabinoid drug formulations and psychedelic treatment protocols. The APIRx takeover is anticipated to be seamless, as the development of assets is congruent with current operational capabilities and our pharmaceutical development strategy targeting FDA registration. Incannex Shareholder Presentation 3

View entire presentation